Spruce Biosciences, Inc. SPRB
Set alert
46.39 USD -0.43 -0.92%
At close · Oct 30
46.39 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
44.69 Day range 46.62
38.98 52-week range 127.00
- YTD
- -46.75%
- 1 year
- -56.75%
- Open
- 46.11
- Prev close
- 46.82
- Mkt cap
- 133.33M
- Vol
- 65.96K
- Avg vol
- 81.10K
- EPS
- -39.12
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 44.69
- High
- 46.62
- Forward P/E
- -0.41
- Beta
- 0.00
- Short ratio
- 0.10
- Inst. own
- 46.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 0.50446
- 200-d avg
- 0.668845
- 1y target
- 1.83
2Y chart
Events in this range
- Nov 11, 2024Earnings: -0.21; estimate -0.27; surprise 22.22%
- Nov 12, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 11, 2024Downgrade: Oppenheimer · Outperform → Perform
- Dec 11, 2024Rating: RBC Capital · Sector Perform → Sector Perform
- Dec 11, 2024Downgrade: JMP Securities · Market Outperform → Market Perform
- Dec 12, 2024Rating: Guggenheim · Neutral → Neutral
- Dec 16, 2024Rating: HC Wainwright & Co. · Neutral → Neutral
- Aug 7, 2025Split: 1 for 75
Signals (59)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Overbought | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 4 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bearish | Apr 21, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 21, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bearish | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 6, 2026 | 7 months ago |
| RSI: Oversold | Feb 20, 2026 | 8 months ago |
| SMA: Bearish | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 13, 2026 | 8 months ago |
| SMA: Bullish | Feb 10, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 16, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 23, 2025 | 10 months ago |
| SMA: Bearish | Nov 28, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| RSI: Overbought | Oct 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Aug 5, 2025 | 1 year ago |
| RSI: Oversold | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 18, 2025 | 1 year ago |
| RSI: Overbought | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| RSI: Oversold | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Apr 15, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 10, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| RSI: Oversold | Mar 26, 2025 | 1 year ago |
| RSI: Oversold | Mar 17, 2025 | 1 year ago |
| RSI: Oversold | Mar 13, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| SMA: Bearish | Feb 26, 2025 | 1 year ago |
| SMA: Bullish | Feb 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 12, 2024 | 1 year ago |
Key statistics
- Market cap
- 15.59M
- Enterprise value
- -40.58M
- Trailing P/E
- 0.00
- Forward P/E
- -0.41
- PEG ratio
- 0.00
- Price / sales
- 2.20
- Price / book
- 0.30
- EPS (TTM)
- -0.95
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.10M
- Revenue growth
- -80.40%
- Free cash flow
- -35.07M
- Total cash
- 60.05M
- Total debt
- 2.96M
- Return on equity
- -57.55%
- Shares outstanding
- 41.30M
- Short % of float
- 0.08%
- 50-day average
- 0.50446
- 200-day average
- 0.668845
Analyst view
Consensus: hold
Hold
Price target (mean) 1.83 -96.0% downside
Now 46.39
- Target (low)
- 1.00
- Target (mean)
- 1.83
- Target (high)
- 3.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
- Strong buy0
- Buy0
- Hold5
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.205.
Financials — quick view
SPRB Revenue — quarterly 0
SPRB Net income — quarterly -16.23M
SPRB EPS — quarterly -6.68
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.27 | -0.21 | +0.06 | +22.22% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | -0.22 | +0.11 | +33.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.33 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.32 | -0.28 | +0.04 | +12.50% |
| May 13, 2024 | Mar 1, 2024 | -0.32 | — | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Dec 12, 2024 | Guggenheim | reit | Neutral | Neutral |
| Dec 11, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| Dec 11, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 12, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sprucebiosciences.com
News
- Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
- Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
- Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target
- Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149
- Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Spruce Biosciences Announces Launch of MPS3BStudy.com
- Spruce Biosciences Launches MPS3BStudy.com, Online Resource For Families And Caregivers Of Children With Sanfilippo Syndrome Type B
- Spruce Biosciences Announces Launch of MPS3BStudy.com
- Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
- Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104
Your note
Sign in to keep a note on SPRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARLTON RALPH WILLIAM III | Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 161,339 |
| GHARIB SAMIR M | President | Conversion of Exercise of derivative security | Dec 15, 2024 | 350,550 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 20, 2024 | 2,550,000 |
| O DONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| ODONNELL NIALL | Director | Purchase | Feb 15, 2023 | 0 |
| SZWARCBERG JAVIER B M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 467,191 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rivervest Venture Management LLC | 7.11% | 2,936,281 | 1.11M | Sep 29, 2024 |
| Carlyle Group Inc. | 7.01% | 2,896,518 | 1.09M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 6.32% | 2,609,125 | 984.94K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 3.05% | 1,259,151 | 475.33K | Sep 29, 2024 |
| Vanguard Group Inc | 2.04% | 843,844 | 318.55K | Sep 29, 2024 |
| Sands Capital Ventures, LLC | 1.91% | 787,007 | 297.10K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 638,558 | 241.06K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 197,187 | 74.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.37% | 153,228 | 57.84K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.10% | 40,000 | 15.10K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 36,510 | 13.78K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 31,503 | 11.89K | Oct 30, 2024 |